drugset / Trial / NCT06095102

A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

NCT06095102

Phase 3 Active not recruiting 311 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

Timeline

Start
2023-10-12
Primary completion
2024-06-19
Completion
2027-02-17

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide 200 mg Oral

Indications